Charles River Laboratories Announces Chief Financial Officer Transition
CRL(NYSE:CRL) WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Chief Financial Officer Transition
Cresco Labs Opens Sunnyside Proctorville, Strengthening Ohio Market Leadership
CRL(NYSE:CRL) CHICAGO--(BUSINESS WIRE)--Cresco Labs Opens Sunnyside Proctorville, Strengthening Ohio Market Leadership
Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer
CRL(NYSE:CRL) WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River collaborates to enhance oncology manufacturing portfolio by advancing development of cell and gene therapies to treat cancer.
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
CRL(NYSE:CRL) WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences
CRL(NYSE:CRL) WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program announced today
Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing
CRLWILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River joins EASYGEN to provide 3D screening expertise, supporting the development of a bedside CAR-T manufacturing platform .
Cresco Labs Closes $325 Million Senior Secured Term Loan Refinancing
CRLCHICAGO--(BUSINESS WIRE)--Cresco Labs Closes $325 Million Senior Secured Term Loan Refinancing
Cresco Labs Announces Commitments to Refinance its Senior Secured Credit Facility
CRLCHICAGO--(BUSINESS WIRE)--Cresco Labs Announces Commitments to Refinance its Senior Secured Credit Facility
Charles River Laboratories Announces Second-Quarter 2025 Results
CRLWILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2025 Results
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment
CRLWILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River today announced a recycling program, developed in partnership with TerraCycle to give new life to single-use plastic cartridges.
Circle Stock Has Popped 271% Since NYSE Debut, Now A KPMG Consultant Says This Is The Next Big Thing After Stablecoins
CRLTarun Anand, KPMG’s Blockchain and Digital Asset Consultant, said stablecoins, real-world asset tokenization and decentralized physical infrastructure networks will be the key cryptocurrency narratives to watch out for in the next few years.
Charles River Labs And CHDI Foundation Announce Extension Of Ongoing Drug Discovery Partnership Into Foreseeable Future
CRLThis Waste Management Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
CRLRedburn Atlantic Upgrades Charles River to Buy, Lowers Price Target to $182
CRLWhat 10 Analyst Ratings Have To Say About Charles River
CRLBarclays Maintains Equal-Weight on Charles River, Raises Price Target to $155
CRLBaird Maintains Neutral on Charles River, Raises Price Target to $140
CRLCharles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs of Demand Stabilization
CRLCharles River shares rise after Q1 adjusted EPS and revenue top estimates; company raises 2025 outlook and adds four directors to its board.
Charles River Laboratories Announces Board Changes and Strategic Review
CRLCharles River Raises FY2025 GAAP EPS Guidance from $4.30-$4.80 to $4.35-$4.85 vs $5.68 Est
CRLCharles River Raises FY2025 Adj EPS Guidance from $9.10-$9.60 to $9.30-$9.80 vs $9.33 Est; Raises FY2025 Sales Guidance from $3.77B-$3.87B to $3.83B-$3.91B vs $3.82B Est
CRLCharles River Q1 Adj. EPS $2.34 Beats $2.08 Estimate, Sales $984.17M Beat $941.97M Estimate
CRL9 Health Care Stocks With Whale Alerts In Today's Session
CRLWall Street Rebounds, JPMorgan Jumps On Strong Q1 Earnings: What's Driving Markets Friday?
CRLWall Street bounced back from early losses, driven by upbeat bank earnings and cooler inflation data, while shrugging off trade war concerns.
'FDA Announces Plan to Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs' - FDA
CRLBarclays Maintains Equal-Weight on Charles River, Lowers Price Target to $145
CRLCharles River Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
CRLMizuho Maintains Neutral on Charles River, Lowers Price Target to $155
CRLDemystifying Charles River: Insights From 10 Analyst Reviews
CRLThis FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
CRLGoldman Sachs Downgrades Charles River to Neutral, Lowers Price Target to $170
CRLCitigroup Upgrades Charles River to Neutral, Raises Price Target to $175
CRLJP Morgan Maintains Neutral on Charles River, Lowers Price Target to $165
CRLBaird Maintains Neutral on Charles River, Lowers Price Target to $173
CRLBarclays Maintains Equal-Weight on Charles River, Lowers Price Target to $160
CRLAnalyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
CRLCharles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.
Charles River Sees FY25 Adjusted EPS Of $9.10-$9.60 Vs. $9.60 Estimate
CRLCharles River Plans To Repurchase Approximately $350M In Common Stock In 2025
CRLCharles River Q4 2024 Adj. EPS $2.66 Beats $2.53 Estimate, Sales $1.003B Beat $983.627M Estimate
CRLAnalyst Expectations For Charles River's Future
CRLBarclays Maintains Equal-Weight on Charles River, Lowers Price Target to $166
CRLWilliam Blair Reiterates Outperform on Charles Riverto Outperform
CRLCharles River Laboratories Sees Prelim. FY25 Revenue To Decline Organically In Similar Range As Estimated In 2024
CRLCharles River Q3 Earnings: CEO Notes Improved Biotech Funding And Stabilizing Demand - Here's Why
CRLCharles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating margin dropped to 11.6% amid restructuring costs.
Charles River Laboratories Raises FY24 Outlook: Sees Adjusted EPS Of $10.10–$10.30 Vs. $10 Estimate (Prior View: $9.90–$10.20)
CRLCharles River Q3 2024 Adj. EPS $2.59 Beats $2.43 Estimate, Sales $1.009B Beat $976.015M Estimate
CRLCharles River: Q1 Earnings Insights
CRLCharles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Charles River Maintains FY22 Adj EPS And Sales Guidance
CRLCharles River Q1 EPS $2.75 Beats $2.71 Estimate, Sales $913.90M Beat $910.10M Estimate
CRLPreview: Charles River's Earnings
CRLCharles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that Charles River will report an earnings per share (EPS) of $2.71.